

# 2018 Acute Coronary Syndrome Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Acute Coronary Syndrome Market

<https://marketpublishers.com/r/2E89364FB3DEN.html>

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 2E89364FB3DEN

## Abstracts

Worldwide, an estimated 2 to 3 million people are hospitalized due to ACS annually. The acute coronary syndrome is a common complication of coronary heart disease. ACS refers to a broad range of diseases including Unstable angina, Non-ST segment elevation MI, ST-segment elevation MI. A sudden decrease in blood flow into the heart is observed, eventually resulting in thrombotic occlusion of a coronary artery. A sustained block of blood flow to the heart causes the death of the muscle tissue.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Acute Coronary Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Acute Coronary Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Acute Coronary Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

## Contents

### 1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES

1.2 List of Tables

### 2 ACUTE CORONARY SYNDROME PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Acute Coronary Syndrome Pipeline Snapshot

2.3 Acute Coronary Syndrome Pipeline by Phase

2.4 Acute Coronary Syndrome Pipeline by Company

2.5 Acute Coronary Syndrome Pipeline by Mechanism of Action

### 3 ACUTE CORONARY SYNDROME- COMPANY WISE PIPELINE ANALYSIS

Actelion Pharmaceuticals Ltd.

advanceCor GmbH

Allergan plc

Ascendia Pharmaceuticals LLC

Bayer AG

Cardiome Pharma Corp.

Cerenis Therapeutics Holding SA

CSL Limited

DalCor Pharmaceuticals Canada Inc.

PT. DEXA Medica

HitGen LTD

LipimetiX Development Inc

MedImmune LLC

Pfizer Inc.

Resverlogix Corporation

Verseon Corporation

### 4 ACUTE CORONARY SYNDROME R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/ License Partner  
Orphan Drug Designation  
Development Phase  
Mechanism of Action  
Current Status  
Ongoing Clinical Trial Details

## **5 RECENT DEVELOPMENTS IN ACUTE CORONARY SYNDROME PIPELINE**

### **6 APPENDIX**

6.1 About VPA Research  
6.2 Sources and Research Methodology

## List Of Figures

### LIST OF FIGURES

Figure 1: Acute Coronary Syndrome Pipeline by Phase, H2- 2018

Figure 2: Acute Coronary Syndrome Pipeline by Companies, H2- 2018

Figure 3: Company Wise Pipeline Drug Phases, H2- 2018

Figure 4: Acute Coronary Syndrome Pipeline by Mechanism of Action, H2- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

## List Of Tables

### LIST OF TABLES

Acute Coronary Syndrome Pipeline by Phase, H2- 2018

Acute Coronary Syndrome Pipeline by Companies, H2- 2018

Acute Coronary Syndrome Pipeline by Mechanism of Action, H2- 2018

Table 1: Actelion Pharmaceuticals Ltd. Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 2: advanceCor GmbH Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 3: Allergan plc Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 4: Ascendia Pharmaceuticals LLC Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 5: Bayer AG Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 6: Cardiome Pharma Corp. Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 7: Cerenis Therapeutics Holding SA Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 8: CSL Limited Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 9: DalCor Pharmaceuticals Canada Inc. Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 10: PT. Dexa Medica Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 11: HitGen LTD Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 12: LipimetiX Development Inc Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 13: MedImmune LLC Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 14: Pfizer Inc. Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 15: Resverlogix Corporation Acute Coronary Syndrome Pipeline Drugs, H2- 2018

Table 16: Verseon Corporation Acute Coronary Syndrome Pipeline Drugs, H2- 2018

## I would like to order

Product name: 2018 Acute Coronary Syndrome Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Acute Coronary Syndrome Market

Product link: <https://marketpublishers.com/r/2E89364FB3DEN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2E89364FB3DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970